2022
DOI: 10.1016/j.phyplu.2022.100303
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical toxicity study of Datura metel L. based Unani formulation Habb-e-Zeequn Nafas used in the treatment of Asthma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…A unani drug for asthma named Habb-e-Zeequn Nafas (HZN), where D. metel is used as the active ingredient, was found to be safer in pre-clinical tests ( Firdaus et al, 2022 ). A newly isolated glycoside from D. metel roots (methyl 3,4-dihydroxyphenylacetate-4-O-[2-O-β-D-apisoyl-6-O-(2-hydroxybenzoyl)]-β-D-glucopyranoside) has anti-inflammatory activity ( Qin et al, 2021 ).…”
Section: Resultsmentioning
confidence: 99%
“…A unani drug for asthma named Habb-e-Zeequn Nafas (HZN), where D. metel is used as the active ingredient, was found to be safer in pre-clinical tests ( Firdaus et al, 2022 ). A newly isolated glycoside from D. metel roots (methyl 3,4-dihydroxyphenylacetate-4-O-[2-O-β-D-apisoyl-6-O-(2-hydroxybenzoyl)]-β-D-glucopyranoside) has anti-inflammatory activity ( Qin et al, 2021 ).…”
Section: Resultsmentioning
confidence: 99%